robust
longlast
protect
immun
respons
week
mer
dna
vaccin
induc
humor
cellular
respons
particip
particip
respect
two
particip
maintain
neutralis
antibodi
end
studi
thu
gener
humor
cellular
immun
respons
might
equat
longterm
protect
phase
dna
vaccin
develop
us
militari
aptli
illustr
advanc
technolog
vaccin
platform
clinic
trial
design
bioinformat
togeth
seriou
invest
stakehold
provid
opportun
rapid
vaccin
develop
evalu
countri
mer
endem
must
invest
serious
human
camel
vaccin
develop
continu
outbreak
mer
coronaviru
year
first
discov
effect
human
vaccin
could
ideal
way
prevent
spread
evolut
viru
logist
issu
small
sporad
number
new
mer
case
differ
geograph
locat
need
overcom
coordin
approach
research
someth
need
advanc
rapidli
current
pace
research
develop
dna
vaccin
candid
mer
coronaviru
vaccin
allow
rapid
design
product
advanc
clinic
within
month
preclin
candid
vaccin
select
encourag
result
phase
mer
dna
vaccin
studi
advanc
quickli
includ
studi
adequ
number
elderli
comorbid
popul
care
consider
safeti
longev
protect
respons
therebi
mitig
futur
outbreak
allevi
diseas
burden
suscept
populationselderli
peopl
immunosuppress
peopl
healthcar
worker
haagman
bl
van
big
studi
biosafeti
facil
limit
restrict
vaccin
test
camel
increasingli
recognis
one
health
approach
need
effect
investig
prevent
control
emerg
zoonot
diseas
context
emerg
zoonos
human
veterinari
medicin
must
work
togeth
erad
mer
coronaviru
dromedari
camel
primari
condit
control
diseas
arabian
peninsula
viru
continu
circul
camel
might
attain
new
mutat
enabl
humantohuman
transmiss
result
gener
superspread
strain
comprehens
mer
prevent
control
effort
focu
human
vaccin
also
camel
vaccin
declar
compet
interest
advanc
dna
vaccin
second
phase
trial
need
overcom
oper
logist
challeng
must
target
risk
succumb
diseas
high
mortal
sever
diseas
seen
mer
posit
correl
age
presenc
comorbid
includ
chronic
liver
kidney
heart
diseas
diabet
immunosuppress
condit
furthermor
host
immun
respons
mer
coronaviru
could
contribut
diseas
sever
outcom
thu
vaccineinduc
immun
respons
popul
highrisk
characterist
could
potenti
harm
effect
barrier
encount
sever
acut
respiratori
syndrom
coronaviru
vaccin
develop
year
ago
might
also
hold
true
mer
coronaviru
therefor
mer
coronaviru
vaccin
must
specif
target
vulner
popul
assess
safeti
gener
liver
failur
thu
suggest
apart
high
viral
load
sever
paracetamolinduc
liver
injuri
could
import
cofactor
liver
failur
patient
yellow
fever
fatal
rate
paracetamol
report
cofactor
acut
liver
failur
due
hepatotrop
virus
b
e
accordingli
follow
therapeut
recommend
could
propos
improv
surviv
symptomat
patient
suspect
yellow
fever
cessat
paracetamol
administr
earli
intraven
administr
nacetylcystein
antidot
paracetamol
hepatotox
patient
intern
normalis
ratio
greater
also
patient
recent
paracetamol
ingest
deni
absent
earli
administr
nacetylcystein
associ
high
surviv
rate
two
independ
uncontrol
short
case
seri
patient
dengu
feveranoth
arbovir
infectionand
earli
acut
liver
failur
declar
compet
interest
